Increasing life expectancy has led to silently progressive neurodegenerative disorders becoming more prominent worldwide. In the case of neurodegenerative disorders like Alzheimer’s disease, Parkinson’s disease, and Huntington’s disease, the urgent need for targeted and effective treatments is more significant than ever.
Major technological advancements have spurred research and development in the biotechnology industry, leading to the discovery of novel therapeutic platforms that can target the root cause of diseases.
With the help of advanced technologies such as artificial intelligence, gene editing, and precision medicine, biotech companies are now better equipped to develop new treatment strategies. One promising approach gaining significant attention in recent years involves targeting the overactive immune system and reducing systemic inflammation to mitigate the detrimental effects of neuroinflammation.
In 2023, the US healthcare industry is again facing several significant challenges, including ongoing high inflation rates, labor shortages, and the persistent impact of the COVID-19 pandemic. Despite continued difficulties, leaders in the space are working to find innovative solutions to improve the current system while looking ahead at the promising future of medicine that appears to have already arrived.
From artificial intelligence-based medicine to breakthroughs in precision neuroscience, we outline key trends expected to shape the healthcare landscape in 2023 and beyond.
The month of June observes Alzheimer’s and Brain Awareness Month recognizing the over 50 million people living with Alzheimer’s disease (AD) and other forms of dementia worldwide. Organizers of the campaign work to ameliorate a global lack of understanding of neurodegenerative diseases; they strive to inform, educate, and provide support for dementia sufferers and their loved ones.
A growing body of research has been able to identify several factors that may contribute to the development of the condition. Diabetes, hypertension, obesity, depression, cognitive inactivity, and other modifiable risk factors have all been associated with dementia, while many others are under investigation.